LEVITRA (vardenafil hydrochloride) is administered orally for the treatment of erectile dysfunction. This monohydrochloride salt of vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).
Viagra, Cialis and Levitra have all been shown to be effective in 60-70% of men with erectile dysfunction. However, as above, it is possible that one medicine will be more or less effective than the others, and therefore it is best to initially try out all three to see which is best.
LEVITRA (vardenafil hydrochloride) is administered orally for the treatment of erectile dysfunction. This monohydrochloride salt of vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).
General Dose Information
For most patients, the recommended starting dose of LEVITRA is 10 mg, taken orally, as needed, approximately 60 minutes before sexual activity. The dose may be increased to a maximum recommended dose of 20 mg or decreased to 5 mg based on efficacy and side effects. The maximum recommended dosing frequency is once per day. Sexual stimulation is required for a response to treatment.
Use With Food
LEVITRA can be taken with or without food.
Use In Specific Populations
Geriatrics
A starting dose of 5 mg LEVITRA should be considered in patients ≥ 65 years of age [see Use In Specific Populations].
Hepatic Impairment
For patients with moderate hepatic impairment (Child-Pugh B), a starting dose of 5 mg LEVITRA is recommended. The maximum dose in patients with moderate hepatic impairment should not exceed 10 mg.
Do not use LEVITRA in patients with severe hepatic impairment (Child-Pugh C) [see WARNINGS AND PRECAUTIONS, Use In Specific Populations and CLINICAL PHARMACOLOGY].
Renal Impairment
Do not use LEVITRA in patients on renal dialysis [see WARNINGS AND PRECAUTIONS, Use In Specific Populations and CLINICAL PHARMACOLOGY].
No comments:
Post a Comment